Q2 2024 Earnings Estimate for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Issued By Wedbush

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Wedbush raised their Q2 2024 earnings per share (EPS) estimates for shares of Kiniksa Pharmaceuticals in a research note issued to investors on Tuesday, April 23rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.06) for the quarter, up from their previous estimate of ($0.16). Wedbush currently has a “Outperform” rating and a $30.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is $0.06 per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at $0.01 EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at $0.02 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.24 EPS, FY2026 earnings at $0.80 EPS and FY2027 earnings at $1.26 EPS.

A number of other research firms also recently weighed in on KNSA. TheStreet upgraded Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Thursday, February 29th. Evercore ISI upped their price objective on Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday.

Kiniksa Pharmaceuticals Stock Up 1.5 %

KNSA stock opened at $17.88 on Thursday. The company has a market cap of $1.26 billion, a P/E ratio of 162.55 and a beta of 0.27. Kiniksa Pharmaceuticals has a twelve month low of $10.65 and a twelve month high of $22.09. The business has a fifty day moving average of $19.27 and a 200-day moving average of $18.00.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.11). Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.32%. The business had revenue of $79.90 million during the quarter, compared to the consensus estimate of $76.97 million. During the same quarter in the previous year, the firm posted ($0.18) EPS. The company’s revenue for the quarter was up 65.4% compared to the same quarter last year.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, CEO Sanj K. Patel sold 12,742 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the transaction, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at $1,517,065.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Sanj K. Patel sold 12,742 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the transaction, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at $1,517,065.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael R. Megna sold 5,126 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $383,242.52. The disclosure for this sale can be found here. Insiders sold 33,109 shares of company stock valued at $709,929 over the last three months. Company insiders own 54.23% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Altitude Crest Partners Inc. bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter worth approximately $7,999,000. Peregrine Capital Management LLC bought a new position in shares of Kiniksa Pharmaceuticals during the first quarter worth approximately $4,657,000. Acadian Asset Management LLC increased its stake in shares of Kiniksa Pharmaceuticals by 916.6% during the third quarter. Acadian Asset Management LLC now owns 226,181 shares of the company’s stock worth $3,919,000 after purchasing an additional 203,933 shares during the period. Granahan Investment Management LLC increased its stake in shares of Kiniksa Pharmaceuticals by 35.2% during the fourth quarter. Granahan Investment Management LLC now owns 722,388 shares of the company’s stock worth $12,671,000 after purchasing an additional 188,174 shares during the period. Finally, Schonfeld Strategic Advisors LLC increased its stake in shares of Kiniksa Pharmaceuticals by 180.1% during the third quarter. Schonfeld Strategic Advisors LLC now owns 208,500 shares of the company’s stock worth $3,622,000 after purchasing an additional 134,070 shares during the period. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.